Johnson & Johnson (JNJ)
| Market Cap | 540.74B |
| Revenue (ttm) | 94.19B +5.1% |
| Net Income | 26.80B +71.1% |
| EPS | 11.03 +71.3% |
| Shares Out | 2.41B |
| PE Ratio | 20.35 |
| Forward PE | 19.46 |
| Dividend | $5.20 (2.32%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 8,154,303 |
| Open | 222.00 |
| Previous Close | 221.49 |
| Day's Range | 220.70 - 225.50 |
| 52-Week Range | 141.50 - 225.50 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 222.18 (-1.01%) |
| Earnings Date | Jan 21, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $222.18, which is a decrease of -1.01% from the latest price.
News
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth in...
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help mor...
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Johnson & Johnson is doing 'great things for patients,' CFO says
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company's performance and President Donald Trump's healthcare agenda on 'The Claman Countdown.' #fox #media #breakingnews #...
Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi
PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that ...
Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The ...
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates
Johnson & Johnson (NYSE:JNJ) on Wednesday reported better-than-expected fourth-quarter earnings.
OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings
Johnson & Johnson (JNJ) posted better-than-expected earnings but still traded to the downside. Diane King Hall points to Stelara as the cause.
J&J expects to hit $100 billion in revenue next year after new strategy pays off
Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with...
J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales
The healthcare company's forecast for 2026 tops Wall Street's expectations.
Johnson & Johnson reports Q4 and Full-Year 2025 results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strong...
Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings
Johnson & Johnson (NYSE: JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.
Is Johnson & Johnson A Dividend Stock, Or Something Else?
Healthcare may be entering early mean reversion, but much of Johnson & Johnson's valuation recovery has already occurred. Post-Kenvue, JNJ is a higher-growth, less dividend-centric business, changing ...
Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)
Johnson & Johnson is downgraded to Hold, as valuation is now stretched after a 50% 12-month rally. JNJ trades above 21x forward EPS, exceeding its long-term average and offering a limited margin of sa...
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new sta...
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATO ® (esketamine) effects on anhedonia in ...
Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
Mar Vista's U.S. Quality strategy returned +0.20% net-of-fees in Q4 2025. The Russell 1000 Index and the S&P 500 Index returned +2.41% and +2.65%, respectively. Alphabet, Johnson & Johnson and Danaher...
Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court
Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical robots.
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver m...
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...